๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
NCT06569485DLBCL
Sun Yat-sen University
Phase 2
38
Guangzhou
2024-05-23
Recruiting
The Effect of Different Body Positions and Channel Sheaths on RIRS
NCT06438497Urolithiasis
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
120
Guangzhou
2024-05-23
Active, closed
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
NCT06382116Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
432
Guangzhou
2024-05-22
Active, closed
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
NCT06414577Nasopharyngeal Cancer
XIANG YANQUN
Phase 2
38
Guangzhou
2024-05-22
Recruiting
Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06911606SCLC, Limited Stage
Guangdong Provincial People's Hospital
Phase 2
45
Guangzhou
2024-05-22
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
NCT06542159Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
Sun Yat-sen University
Phase 2
130
Guangzhou
2024-05-22
Not yet open
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
NCT06329947Advanced Pancreatic Cancer
Rui-hua Xu, MD, PhD
Phase 2
37
Guangzhou
2024-05-22
Recruiting
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients
NCT06344091Local Analgesia Via Infiltration
Jiangsu HengRui Medicine Co., Ltd.
Phase 4
232
Guangzhou
2024-05-21
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Recruiting
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT06516133Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
494
Guangzhou
2024-05-17
Active, closed
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
NCT06396039Relapsing Multiple Sclerosis
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Recruiting
Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
NCT06364956Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
36
Guangzhou, Wuhan, Changsha
2024-05-15
Recruiting
Prebiotics and the Management of Hyperuricemia
NCT06420401Subjects With Hyperuricemia
Sun Yat-sen University
Not applicable
160
Guangzhou
2024-05-15
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naรฏve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138Hematologic Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
NCT06383780Nasopharyngeal Carcinoma
XIANG YANQUN
Phase 3
90
Guangzhou
2024-05-15
Active, closed
Phase 3 Study of ALXN1850 in Treatment-Naรฏve Pediatric Participants With HPP
NCT06079359Hypophosphatasia
Alexion Pharmaceuticals, Inc.
Phase 3
30
Beijing, Guangzhou, Shanghai, Shenzhen
2024-05-14
Recruiting
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
NCT06202625Thrombocytopenia, Stem Cell Transplant Complications
Peking University People's Hospital
Phase 2/3
142
Beijing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-05-13
Recruiting
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
NCT07234162Peripheral T-cell Lymphoma
Dizal Pharmaceuticals
Phase 3
218
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-05-13
Recruiting
Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
NCT05990556Glioblastoma, Meningeal Arteries
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
20
Guangzhou
2024-05-11
Recruiting
GPC3/Mesothelin-CAR-ฮณฮดT Cells Against Cancers
NCT06196294Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-05-10
Recruiting
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
NCT06289062Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation
Tongji Hospital
Phase 2
40
Guangzhou, Wuhan
2024-05-08
Recruiting
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
NCT06195384Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-05-08
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
Sanofi
Phase 3
1,541
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan
2024-05-08
Recruiting
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
NCT06376136Advanced Solid Tumors
Bio-Thera Solutions
Phase 1/2
216
Guangzhou
2024-05-08
Active, closed
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06316531HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
274
Guangzhou
2024-05-08
Recruiting
AMT-116 in Patients with Solid Tumors
NCT06782334Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1/2
144
Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou
2024-05-07
Recruiting
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
NCT06300320Chronic Graft Versus Host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
65
Hefei, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Xiangyang, Taian, Shanghai
2024-05-07
Recruiting
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
244
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-05-07
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,700
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-05-06
Not yet open
Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer
NCT06255379Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer
Guangzhou University of Traditional Chinese Medicine
Phase 2
52
Guangzhou
2024-05-06
By invitation
A Prospective, Randomized, Open, Parallel-controlled, Superior-efficacy Clinical Study of Radical Sigmoidectomy for Sigmoid Cancer Versus Radical Sigmoidectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracing Dissection in the Treatment of Sigmoid Cancer
NCT06396806Sigmoid Cancer
Sun Yat-sen University
Not applicable
1,072
Guangzhou
2024-05-06
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
Merck Sharp & Dohme LLC
Phase 3
450
Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang
2024-05-03
Recruiting
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
NCT06397235Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
130
Guangzhou
2024-05-01
Recruiting
Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Disorders of Consciousness
NCT07284732Disorders of Consciousness
Zhujiang Hospital
Not applicable
20
Guangzhou
2024-05-01
Not yet open
Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
NCT05707468Oligometastatic Prostate Carcinoma
Changhai Hospital
Not applicable
200
Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai
2024-05-01
Not yet open
KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
NCT06370026Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase EARLY_PHASE1
12
Guangzhou
2024-05-01
Recruiting
De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.
NCT06353685De-escalated Radiotherapy; Head and Neck Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
103
Guangzhou
2024-05-01
Recruiting
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
NCT06397222Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
23
Guangzhou
2024-05-01
Recruiting
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
Recruiting
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
NCT06592417Advanced Malignant Solid Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
140
Fuzhou, Guangzhou
2024-04-30
Recruiting
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385925Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Recruiting
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dizal Pharmaceuticals
Phase 2
155
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian
2024-04-29
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
NCT06298968Intrahepatic Cholangiocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2
38
Guangzhou
2024-04-26
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069Acute Myeloid Leukemia
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
Eli Lilly and Company
Phase 3
450
Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai
2024-04-26
Recruiting
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
NCT06685978Hyperplasia of Mammary Glands
Tasly Pharmaceutical Group Co., Ltd
Phase 3
430
Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing
2024-04-26
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Active, closed
A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06114511Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
78
Guangzhou
2024-04-24
Active, closed
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
NCT06280716Atopic Dermatitis
Eli Lilly and Company
Phase 3
301
Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Haikou, Shijiazhuang
2024-04-24
Recruiting
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
NCT06781151Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent
Sun Yat-sen University
Observational
200
Guangzhou, Shenzhen
2024-04-24
Active, closed
Evolve China PMCF Study
NCT06368622Intracranial Aneurysm
Stryker Neurovascular
Observational
500
Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao
2024-04-24
Recruiting
Safety and Effectiveness of Mesenchymal Stem Cells in Blood Purification for the Treatment of Liver Failure
NCT06904755Liver Failure
Kebo Zhong
Phase 1
10
Guangzhou
2024-04-23
Active, closed
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448Lung Cancer
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
Cohort Study on Neuroimmune Diseases in the Reproductive Age
NCT07653984Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis, Autoimmune Encephalitis, Myasthenia Gravis
Third Affiliated Hospital, Sun Yat-Sen University
Observational
100
Guangzhou
2024-04-21
Recruiting
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
NCT06269211Carcinoma, Non-Small-Cell Lung
Ruijin Hospital
Phase 2
29
Guangzhou, Shanghai
2024-04-20
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
641
Beijing, Changsha, Cheng Du Shi, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2024-04-18
Active, closed
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
NCT06394414Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
Active, closed
Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study
NCT06451302Ewing Sarcoma, Risk Stratification
Yizhuo Zhang
Not applicable
100
Guangzhou
2024-04-17
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
argenx
Phase 3
119
Beijing, Changchun, Chongqing, Fuzhou, Guangxi, Guangzhou, Guiyang, Ningbo
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot
2024-04-16
Recruiting
Individualized Elective Neck Irradiation in NPC Patients
NCT06241612Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
470
Guangzhou
2024-04-16
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Baotou, Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Guangzhou
2024-04-12
Recruiting
Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma
NCT06364384Rectal Squamous Cell Carcinoma
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
20
Guangzhou
2024-04-12
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Active, closed
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
NCT06251180B-cell Non-Hodgkin Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
112
Guangzhou
2024-04-10
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guรฉrin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
272
Beijing, Cheng Du Shi, Chongqing, Guangzhou, Shenyang, Tianjin, Wenzhou, Wuhan
2024-04-09
Recruiting
Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Reducing Recurrence of Colorectal Adenoma (CRA)
NCT06205862Fecal Microbiota Transplantation, Colorectal Adenoma, Gastrointestinal Microbiome
Shenzhen Hospital of Southern Medical University
Phase 2
466
Guangzhou, Shenzhen, Shunde
2024-04-09
Recruiting
Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients
NCT06315231Post-stroke Cognitive Impairment
Simcere Pharmaceutical Co., Ltd
Phase 2
226
Fuyang, Hefei, Huangshan City, Guangzhou, Wuzhou, Shijiazhuang, Zhumadian, Nanchang
2024-04-08
Recruiting
Modified Intermittent Eating on Weight Loss (INTEREST-3 Trial)
NCT06302803Obesity
Nanfang Hospital, Southern Medical University
Not applicable
225
Guangzhou
2024-04-07
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
NCT06883487Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian Cancer, Observing the Effectiveness of Targeted HER2 ADC Drugs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
144
Guangzhou
2024-04-07
Not yet open
Efficacy and Safety of Intraparenchymal Portal Vein Covered Stents in Treating Portal Hypertension and Its Complications
NCT06320912Portal Hypertension
Shanghai Shenqi Medical Technology Co., Ltd
Not applicable
258
Guangzhou
2024-04-05
Recruiting
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
NCT06313190Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-04-05
Active, closed
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132Generalized Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc.
Phase 2/3
80
Guangzhou
2024-04-04
Recruiting
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
NCT06483347Lung Cancer, Inoperable Disease
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guangzhou
2024-04-04
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
Not yet open
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
NCT06317896Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
Zhujiang Hospital
Observational
82
Foshan, Guangzhou
2024-04-01
Not yet open
Transfusion in Cardiac Valve Surgery
NCT06332547Cardiac Surgery With Cardiopulmonary Bypass, Valve Heart Disease
Guangdong Provincial People's Hospital
Not applicable
1,600
Guangzhou
2024-04-01
Recruiting
Interventional Software for Multi-immunotherapy of Solid Tumors
NCT06478108Lung Cancer, Liver Cancer, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3
60
Guangzhou
2024-04-01
Recruiting
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
NCT06383728Lung Cancer, Carcinoma, Squamous Cell
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
51
Guangzhou
2024-04-01
Active, closed
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
NCT06300424Non Small Cell Lung Cancer, EGFR Gene Mutation
Guangdong Provincial People's Hospital
Phase 2
32
Guangzhou
2024-04-01
Recruiting
A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
NCT06308328Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
Nanfang Hospital, Southern Medical University
Observational
718
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Shanghai, Chengdu
2024-04-01
Recruiting
Factors Associated With Posttransplant Cardiac Outcomes
NCT06290154Cardiovascular Diseases, Liver Transplantation
Sun Yat-sen University
Observational
200
Guangzhou
2024-04-01
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
Alexion Pharmaceuticals, Inc.
Phase 3
579
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Recruiting
Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
NCT05514015Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
78
Guangzhou
2024-03-29
Not yet open
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
NCT06298266Relapsed or Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital
Phase EARLY_PHASE1
15
Guangzhou
2024-03-29
Recruiting
The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy
NCT06418698Stroke, Acute, Ischemic Stroke, Vascular Diseases, Central Nervous System Diseases
Zhujiang Hospital
Observational
434
Guangzhou
2024-03-28
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Recruiting
Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)
NCT06284642Aneurysmal Subarachnoid Hemorrhage
Second Affiliated Hospital of Nanchang University
Phase 4
424
Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-03-28
Recruiting
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
NCT06307925Advanced Solid Tumor
HC Biopharma Inc.
Phase 1
122
Guangzhou
2024-03-27
Recruiting
A Study of CS23546 in Subjects With Advanced Tumors
NCT06245122Advanced Tumors
Chipscreen Biosciences, Ltd.
Phase 1
156
Guangzhou
2024-03-27
Recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
240
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Recruiting
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma
NCT06323369Head and Neck Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
154
Guangzhou
2024-03-25
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Recruiting
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
NCT06244264Spinal Metastases, Blood Transfusion Complication, Lung Cancer, Surgery
Guangdong Provincial People's Hospital
Not applicable
118
Guangzhou
2024-03-15
Rows per page Showing 1901–2000 of 3318
Previous 18 19 20 21 22 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=20

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.